Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Change in Accured Expenses: 2022-2024

Historic Change in Accured Expenses for Mereo BioPharma Group (MREO) over the last 3 years, with Dec 2024 value amounting to -$1.2 million.

  • Mereo BioPharma Group's Change in Accured Expenses rose 15.03% to -$673,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$839,000, marking a year-over-year increase of 61.85%. This contributed to the annual value of -$1.2 million for FY2024, which is 67.89% down from last year.
  • Per Mereo BioPharma Group's latest filing, its Change in Accured Expenses stood at -$1.2 million for FY2024, which was down 67.89% from -$710,000 recorded in FY2023.
  • In the past 5 years, Mereo BioPharma Group's Change in Accured Expenses registered a high of $844,000 during FY2022, and its lowest value of -$1.2 million during FY2024.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$710,000 (2023), whereas its average is -$352,667.
  • Data for Mereo BioPharma Group's Change in Accured Expenses shows a maximum YoY tumbled of 184.12% (in 2023) over the last 5 years.
  • Mereo BioPharma Group's Change in Accured Expenses (Yearly) stood at $844,000 in 2022, then slumped by 184.12% to -$710,000 in 2023, then crashed by 67.89% to -$1.2 million in 2024.